TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection~* HER2-positive breast cancer~* Eastern cooperative Oncology Group (ECOG) performance status 0, 1 or 2~* LVEF of at least 50 percent (%)~Exclusion Criteria:~* Previous systemic non-hormonal anti-cancer therapy for metastatic or locally recurrent disease~* Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence less than or equal to (\</=) 6 months~* Previous approved or investigative anti-HER2 agents in any breast cancer treatment setting, except for trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting~* Disease progression while receiving trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting~* History of persistent Grade 2 or higher (National Cancer Institute Common Toxicity Criteria \[NCI-CTC\], Version 4.0) hematological toxicity resulting from previous adjuvant or neoadjuvant therapy~* Central nervous system (CNS) metastases~* Current peripheral neuropathy of Grade 3 or greater (NCI-CTC, version 4.0)~* History of other malignancy within the last 5 years prior to first study drug administration, except for carcinoma in situ of the cervix or basal cell carcinoma~* Inadequate bone marrow, liver or renal function~* Uncontrolled hypertension~* Hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pertuzumab + Trastuzumab + Taxane (Type: EXPERIMENTAL): Participants will receive pertuzumab and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. Taxane chemotherapy can be either docetaxel, paclitaxel or nab-paclitaxel as per investigator's choice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Satisfaction With Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl Sedation for Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inflammatory Bowel Disease (IBD) or suspected IBD~* Planned Endoscopy~* Candidate for propofol sedation~* willingness to be randomized~* Ability to complete questionnaire~Exclusion Criteria:~* Allergy to drugs~* American Society of Anesthesiologists Class III~* Body Mass Index \> 35~* Ventricular retention~* Acute condition~* Severe Chronic obstructive pulmonary disease~* Sleep apnea~* Potentially difficult airway or previous difficulty with anesthesia~* Pregnancy~* \<18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Propofol (Type: EXPERIMENTAL): Propofol in refract doses. Induction: 10-60 mg supplemented with 10-30 mg following an age correlated algorithm. Maintenance with refract bolus of 10-20 mg every 1-2 minutes after assessed need and condition
- Fentanyl and Midazolam (Type: ACTIVE_COMPARATOR): 0.025-0.05 mg of Fentanyl i.v. minimum 5 minutes before procedure as a single shot. Midazolam 1-2 mg i.v. for induction and 0.5-1 mg i.v. for maintenance after assessing needs and condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Europeans aged 18 years or older with moderate to severe hypertension (HTN)~Exclusion Criteria:~* Female patients of childbearing potential pregnant, lactating or planning to become pregnant during the trial period.~* Patients with serious disorders which may limit the ability to evaluate the efficacy or safety of the study medication, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological or oncological, neurological and psychiatric diseases.~* Patients having a history of the following within the last six months:~  * myocardial infarction,~ * unstable angina pectoris,~ * percutaneous coronary intervention,~ * severe heart failure,~ * hypertensive encephalopathy,~ * cerebrovascular accident (stroke) or~ * transient ischaemic attack.~* Patients with clinically significant abnormal laboratory values at screening.~* Patients with secondary HTN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4 (Type: EXPERIMENTAL): olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
- 1 (Type: EXPERIMENTAL): olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
- 3 (Type: EXPERIMENTAL): olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
- 2 (Type: EXPERIMENTAL): olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-04449913 In Select Hematologic Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with select advanced hematologic malignancies who are refractory, resistant or intolerant to prior therapies. They may be newly diagnosed and previously untreated, but not eligible for standard treatment options, or for whom standard therapies are not anticipated to result in a durable response.~* ECOG performance status 0 to 2~* Adequate organ function~Exclusion Criteria:~* Patients with active CNS disease~* Patient with active malignancy with the exception of basal cell carcinoma, non melanoma skin cancer, carcinoma in situ cervical or skin cancer~* Active GVHD other than Grade 1 skin involvement~* Known malabsorption syndrome~* Patient has an active, life threatening or clinically significant uncontrolled systemic infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate (as classified by the Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] Guidelines, 2007) chronic obstructive pulmonary disease (COPD) and:~  1. Smoking history of at least 10 pack-years.~ 2. Forced expiratory volume in 1 second (FEV1) \< 80% and ≥ 50% of the predicted normal value.~ 3. Post-bronchodilator FEV1/Force vital capacity (FVC) \< 0.7.~Exclusion Criteria:~* Patients who have had a COPD exacerbation requiring systemic glucocorticosteroid treatment or antibiotics and/or hospitalization in the 6 weeks prior to screening.~* Patients who have had a respiratory tract infection within 6 weeks prior to screening.~* Patients with concomitant pulmonary disease.~* Patients with alpha-1-antitrypsin deficiency.~* Patients with contraindications for tiotropium treatment.~* Patients with a history of hypersensitivity to any of the study drugs or to drugs from similar drug classes.~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 150 μg-tiotropium 18 μg-placebo (Type: EXPERIMENTAL): Patients received indacaterol 150 μg once. After a 5-9 days washout period, patients received tiotropium 18 μg once. After a second 5-9 days washout period, patients received placebo (matching indacaterol) once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
- Tiotropium 18 μg-placebo-indacaterol 150 μg (Type: EXPERIMENTAL): Patients received tiotropium 18 μg once. After a 5-9 days washout period, patients received placebo (matching indacaterol) once. After a second 5-9 days washout period, patients received indacaterol 150 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
- Placebo-indacaterol 150 μg-tiotropium 18 μg (Type: EXPERIMENTAL): Patients received placebo (matching indacaterol) once. After a 5-9 days washout period, patients received indacaterol 150 μg once. After a second 5-9 days washout period, patients received tiotropium 18 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent must be obtained prior to participation~* Able to complete adequate fundus photographs and retinal images~* Diagnosis of type 1 or 2 Diabetes Mellitus (DM) and HbA1c less than or equal to 12% at screening~* DM treatment stable for at least 3 months~* PDR diagnosis with no previous PRP treatment in the study eye~Exclusion Criteria:~* Concomitant conditions or ocular disorders in the study eye at Screening or Baseline that could compromise a response to study treatment.~* Presence of diabetic macular edema in the study eye~* Active infection or inflammation in the study eye~* Uncontrolled glaucoma (IOP greater than 25 mmHg)~* Intravitreal anti-VEGF treatment within 6 months~* Treatment with intraocular corticosteroids~* End stage renal disease requiring dialysis or kidney transplant~* Uncontrolled blood pressure~* Systemic anti-VEGF therapy at any time~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brolucizumab 6 mg (Type: EXPERIMENTAL): Intra-vitreal injection. 3 x q6w loading injections, followed by q12w maintenance through Week 90
- Panretinal photocoagulation laser Arm (Type: ACTIVE_COMPARATOR): Initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Serum and Urine N-telopeptide Marker

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Consent to participate in the study~* Participants limited to subjects in the CCF~* Age between and inclusive of 18 and 85 years of age~* No gender exclusion~* Patients diagnosed with Osteopenia on DEXA scan who have not been on any medical therapy in the past~* Presence of normal vitamin D levels, kidney function, and parathyroid hormone levels (per our reference ranges)~Exclusion Criteria:~* Prior history of medical therapy for osteopenia~* Prior radiation therapy~* Prior history of bone fracture~* History of high risk medication associated with increased risk of fracture~* Presence of abnormal vitamin D levels, kidney function, and parathyroid hormone~* Pregnancy status (verbal)~* Those with medical co-morbidities that increase the risk of fracture will be excluded and these include but are not limited to: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, diabetes mellitus, hyperparathyroidism, chronic kidney disease, pituitary disease, multiple myeloma, leukemia, lymphoma, thalassemia major, HIV/AIDS, malabsorption, Inflammatory bowel disease, chronic obstructive pulmonary disease, hypogonadism, chronic liver disease, untreated hyperthyroidism, and those with chronic immobility

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Osteopenia, no past medical therapy (Type: None): Patients diagnosed with osteopenia on DEXA scan who have not been on any medical therapy in the past

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EEG Cap for Identification of Non-Convulsive Status Epilepticus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients with suspected NCSE in the Mayo Clinic Florida hospital, emergency room or intensive care unit.~2. Age: Patients of 18 years or older will be included in this study~3. Education: All education levels will be included~Exclusion criteria:~1. Patients younger than 18 years of age.~2. Patients with open head trauma.~3. Patients with anatomy that would preclude EEG cap placement.~4. Patients excluded for anatomical or age-related reasons will be tracked to determine applicability of the EEG cap to the patient population at Mayo Clinic.~5. Pregnant females~6. Large head size not amenable to cap placement~7. Scalp infection~8. Inability to obtain informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EEG Cap (Type: OTHER): Single arm study, where every participant gets assessed by EEG cap and then standard EEG. Some subjects may be treated with anti-seizure medications before standard EEG, due to ethical responsibility, if clear NCSE is identified on cap EEG. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of BBB Opening With the SonoCloud

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Age greater than 18 years.~* Subjects with recurrent glioma who have failed standard therapy with surgery and/or treatment with radiation and temozolomide.~* Patient eligible for Carboplatin-based chemotherapy~* Contrast-enhanced tumor less than 35 mm in diameter~* No risk of cerebral herniation~* Able to tolerate pre/post procedure steroid treatment~* Social security affiliated (in France)~* Able and willing to give signed and informed consent~* Normal biological status~* Hemoglobin ≥ 10 g/dl~* Platelets ≥ 100000/mm3~* Neutrophils ≥ 1500/mm3~* Normal creatine clearance ≥ 60ml/mn~* ASAT \< 3 N~* ALAT \< 3 N~* Normal Bilirubin Level \< 1.5 N~* Alkaline Phosphatase \< 3 N~* INR \< 1.5~* Prothrombin Level ≥ 70%~Exclusion criteria:~* Allergic to Iodine, Gadolinium, Xylocain~* Contra-indications to echographic contrast agent (microbubbles)~* Severe Renal insufficiency~* Hepatic insufficiency~* Possible toxic treatment for CNS~* Previously infected surgical field~* Uncontrolled epilepsy~* MRI contra-indications~* Hemostasis troubles thrombopenia \<75.000, TP \<60%, INR \>1.5, anti-platelet or anticoagulant therapy on-going)~* Active phlebitis or active pulmonary embolism~* Pregnant or currently breast-feeding~* Patients under judicial protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SonoCloud + carboplatin (Type: EXPERIMENTAL): SonoCloud : dose escalation Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Presence of active clinical synovitis in at least 2 joints, 1 of which must have been a small joint, for a minimum of 8 weeks prior to screening~* Onset of persistent symptoms ≤ 2 years prior to screening~* Positive test result for anticyclic citrullinated peptides 2~* Methotrexate naive or with minimum exposure to methotrexate, defined as no more than 10 mg/week for ≤4 weeks and no methotrexate dose for 1 month prior to screening visit~* Biologic naive, including no treatment with an investigational biologic prior to screening~* Disease Activity Score 28 based on C-reactive protein score ≥3.2 at screening~* Withdrawal from any treatment with chloroquine, hydroxychloroquine, and/or sulfasalazine (wash-out) for a minimum of 28 days prior to randomization~* If receiving oral corticosteroids, on a stable low dose (≤ 10 mg/day prednisone equivalent) for at least 4 weeks~* Able to undergo magnetic resonance imaging~Key Exclusion Criteria:~* Meeting diagnostic criteria for other rheumatic disease (eg, lupus erythematosus)~* Treatment with an intravenous, intramuscular, or intraarticular corticosteroid within 4 weeks prior to randomization~* Scheduled for or anticipating joint replacement surgery~* Presence of concomitant illness likely to require systemic glucocorticosteroid therapy during the study, in the opinion of the investigator~* History of malignancy in the last 5 years~* Any serious bacterial infection within the last 3 months not treated or resolved with antibiotics, or any chronic or recurrent bacterial infection~* At risk for tuberculosis~* Evidence of active or latent bacterial or viral infection at the time of potential enrollment, including human immunodeficiency or herpes zoster virus or cytomegalovirus that resolved less than 2 months prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abatacept, 125 mg, plus methotrexate, 2.5 mg (Type: ACTIVE_COMPARATOR): Participants received abatacept, 125 mg subcutaneously, plus methotrexate, 2.5 mg orally as tablets, once weekly, during the 12-month Treatment Period
- Methotrexate, 2.5 mg, plus abatacept placebo (Type: ACTIVE_COMPARATOR): Participants received methotrexate, 2.5 mg, orally as tablets, plus abatacept placebo subcutaneously, once weekly during the 12-month Treatment Period
- Abatacept, 125 mg, plus methotrexate placebo (Type: ACTIVE_COMPARATOR): Participants received abatacept, 125 mg subcutaneously, plus methotrexate placebo tablets orally, once weekly during the 12-month Treatment Period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete